Comparison of the Therapeutic Effects of Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells on Renal Fibrosis
International Journal of Molecular Sciences · 29.11.2023 · 24 (23) · 16920
DOI: 10.3390/ijms242316920 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.11.2023. Verfasst von Maria Yoshida und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Mesenchymal Stem Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Mesenchymal stem cells (MSCs) have attracted a great deal of interest as a therapeutic tool for renal fibrosis. Although both adipose-derived and bone marrow-derived MSCs (ADSCs and BMSCs, respectively) suppress renal fibrosis, which of these two has a stronger therapeutic effect remains unclear. This study aimed to compare the antifibrotic effects of ADSCs and BMSCs extracted from adipose tissue and bone marrow derived from the same rats. When cultured in serum-containing medium, ADSCs had a more potent inhibitory effect than BMSCs on renal fibrosis induced by ischemia-reperfusion injury in rats. ADSCs and BMSCs cultured in serum-free medium were equally effective in suppressing renal fibrosis. Mice infused with ADSCs (serum-containing or serum-free cultivation) had a higher death rate from pulmonary embolism than those infused with BMSCs. In vitro, mRNA levels of tissue factor, tumor necrosis factor-α-induced protein 6 and prostaglandin E synthase were higher in ADSCs than in BMSCs, while that of vascular endothelial growth factor was higher in BMSCs than in ADSCs. Although ADSCs had a stronger antifibrotic effect, these findings support the consideration of thromboembolism risk in clinical applications. Our results emphasize the importance of deciding between ADSCs and BMSCs based upon the target disease and culture method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
- Department of Stem Cell Biology and Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
- TWOCELLS Company, Limited, 16-35 Hijiyama-honmachi, Minami-ku, Hiroshima 732-0816, Japan.
ORCID-Profile: Maria Yoshida, Ayumu Nakashima, Kensuke Sasaki
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Yoshida, M., Nakashima, A., Ishiuchi, N., Miyasako, K., Morimoto, K., Tanaka, Y., Sasaki, K., Maeda, S., & Masaki, T. (2023). Comparison of the Therapeutic Effects of Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells on Renal Fibrosis. International Journal of Molecular Sciences, 24(23), 16920. https://doi.org/10.3390/ijms242316920
Vancouver
Yoshida M, Nakashima A, Ishiuchi N, Miyasako K, Morimoto K, Tanaka Y, et al. Comparison of the Therapeutic Effects of Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells on Renal Fibrosis. International Journal of Molecular Sciences. 2023;24(23):16920. doi:10.3390/ijms242316920
BibTeX
@article{Yoshida2023,
author = {Yoshida, Maria and Nakashima, Ayumu and Ishiuchi, Naoki and Miyasako, Kisho and Morimoto, Keisuke and Tanaka, Yoshiki and Sasaki, Kensuke and Maeda, Satoshi and Masaki, Takao},
title = {Comparison of the Therapeutic Effects of Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells on Renal Fibrosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {23},
pages = {16920},
doi = {10.3390/ijms242316920}
}
EUVIMED